Correlates of protection and determinants of SARS-CoV-2 breakthrough infections 1 year after third dose vaccination

Table 2 Summary of multivariable Cox regression models to assess the association of antibody levels with breakthrough infection in individuals vaccinated with two or three doses of mRNA vaccine

Isotype	Antigen	Variant	HR	Upper CI	Lower CI	p-value
IgA	N	Wuhan	0.73	1.65	0.32	0.4508
IgA	RBD	Wuhan	0.61	0.90	0.41	0.0126
IgA	S	Wuhan	0.57	0.86	0.38	0.0068
IgA	S1	Wuhan	0.63	0.94	0.43	0.0220
IgA	S2	Wuhan	0.68	1.05	0.44	0.0784
IgG	N	Wuhan	0.70	1.23	0.39	0.2158
IgG	RBD	Wuhan	0.27	0.54	0.14	0.0002
IgG	S	Wuhan	0.25	0.57	0.11	0.0008
IgG	S1	Wuhan	0.24	0.53	0.11	0.0003
IgG	S2	Wuhan	0.38	0.75	0.19	0.0051
IgA	S	Delta	0.61	0.96	0.39	0.0334
IgG	S	Delta	0.30	0.66	0.14	0.0026
IgA	S	Omicron	0.20	0.56	0.07	0.0021
IgG	S	Omicron	0.06	0.26	0.01	0.0001

Covariates for adjustment included age, comorbidities, chronic medication, sex, smoking, infection, time since last infection, vaccination with 3 doses (ref: 2 doses), time since last dose. N = 277. Among the 277 individuals included in the model, there were 75 breakthrough infections
HR hazard ratio

ISSN: 1741-7015